Superbugs & Superdrugs — SMi’s 22nd Annual Superbugs & Superdrugs Conference

As one of the most impactful pharmaceuticals for maintaining public health, antibiotics have been around since early 20th century and have since shown a need for significant progress in recent years. This is mainly due to its broad and indiscriminate use which has slowly given birth to multi- to extensively-drug resistant bacteria rendering our current last-resort antibiotic arsenal, including colistin, carbapenems, 3rd and 4th generation cephalosporins, useless. This year’s event aims to showcase a suite of sessions focused on novel drugs and approaches, particularly highlighting non-traditional and traditional therapies that provide an innovative means to spearhead the issue. The conference will also place significant emphasis on the much-needed support for innovative approaches such as sessions tackling the funding and support and the regulation that provides guidance towards the goal of ameliorating the continued rise of anti-microbial resistance AMR. It is crucial to bring industry leaders together to discuss the strategies in place that reduce AMR, evaluate the role pharmaceutical companies and funding bodies play in reducing AMR, learn about new diagnostics approaches to identify AMR and consider novel candidates and alternatives to anti-microbials. Join us in March 2020, along with leaders from the pharmaceutical industry, academia, regulatory and funding bodies, and public-private partnerships to discuss the way forward.

Topics: Resistance; superbugs; superdrugs; mrsa; infectious diseases; investment; smart materials, infection, drug discovery, antibacterial, antimicrobial, anti-infective, multidrug resistance, MDR, diagnostics, immunization, inhibitors, antibiotic, resistance, antibiotic resistance, vaccine, bacterial, infections, drive a-b, genome sequencing, multi-resistant gram-negative, BARDA, Microbiota, EBOLA, bacteria, biotech, biomedical, pem, disease, amr, ppp, health, containment, microbiology, hepatitis, hcv, clinical, lab, gram positive, gram negative, fungi, fungal, population, contamination, viral, virus, amr, zika, fda, pathogen